Clinical trial · no report yet · Phase 3
NCT04784715
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
- NCT04784715 ↗
- Active not recruiting
- AstraZeneca
- 347 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 130 | |
| X threads | 122 | |
| Podcasts | 86 | |
| X videos | 9 |
The trial
ClinicalTrials.gov- Official title
- Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Breast Cancer; HER2-positive; Metastatic
- Interventions
- Trastuzumab deruxtecan; Placebo; Taxane; Pertuzumab; Trastuzumab
- Arms
- Arm A · Experimental
- Arm B · Experimental
- Arm C · Active comparator
- Enrollment
- 1,157
- Primary outcomes
- Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment
- Sponsor
- AstraZeneca with Daiichi Sankyo
- Start
- Apr 26, 2021
- Primary completion
- Nov 11, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04784715 · updated Jul 30, 2026
Publications
linked from the registry- Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, Park YH, Rimawi MF, Saura C, Schneeweiss A, Toi M, Chae YS, Kemal Y, Chaudhari M, Sendur MAN, Yamashita T, Casalnuovo M, Danso MA, Liu J, Shetty J, Herbolsheimer P, Loibl S; DESTINY-Breast09 Trial Investigators. Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2026 Feb 5;394(6):551-562. doi: 10.1056/NEJMoa2508668. Epub 2025 Oct 29. PubMed 41160818